Eva Vieser

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf et al. · OncoImmunology · 2018 · 176 citations · Full text

Medicine, Oncology, Pharmacology +17

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

Maria Amann, Matthias Friedrich, Petra Lutterbuese et al. · Cancer Immunology Immunotherapy · 2008 · 40 citations · Full text

Life Sciences, Cell Biology, Immunology +10

A phase I study of  EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors.

Walter Fiedler, M. Wolf, Maxim Kebenko et al. · Journal of Clinical Oncology · 2012 · 36 citations

Medicine, Oncology, Pharmacology +17

Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer.

Walter Fiedler, Birgit Ritter, Ruth Seggewiss et al. · Journal of Clinical Oncology · 2010 · 23 citations

Medicine, Oncology, Pharmacology +17

How The Bioanalytical Scientist Plays A Key Role in Interdisciplinary Project Teams in The Development of Biotherapeutics – A Reflection of The European Bioanalysis Forum

Sherri Dudal, Roland F. Staack, Daniela Stoellner et al. · Bioanalysis · 2014 · 10 citations

Pharmacy, Pharmacology, Analytical Chemistry +13